PMID- 36338523
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221108
IS  - 2692-3114 (Electronic)
IS  - 2692-3114 (Linking)
VI  - 3
IP  - 5
DP  - 2022
TI  - Potential role of resveratrol and its nano-formulation as anti-cancer agent.
PG  - 643-658
LID - 10.37349/etat.2022.00105 [doi]
AB  - The uncontrolled and metastatic nature of cancer makes it worse and more 
      unpredictable. Hence, many therapy and medication are used to control and treat 
      cancer. However, apart from this, many medications cause various side effects. In 
      America, nearly 8% of patients admitted to the hospital are due to side effects. 
      Cancer is more seen in people residing in developed countries related of their 
      lifestyle. There are various phytoconstituents molecules in which resveratrol 
      (RSV) is the best-fitted molecule for cancer due to its significantly less 
      adverse effect on the body. RSV inhibits the initiation and progression of cell 
      proliferation due to the modulation of various pathways like the phosphoinositol 
      3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) 
      pathway. RSV downgraded cell cycle-regulated proteins like cyclin E, cyclin D1, 
      and proliferating cell nuclear antigen (PCNA) and induced the release of 
      cytochrome c from the mitochondria, causing apoptosis or programmed cell death 
      (PCD). A great benefit comes with some challenges, hence, RSV does suffer from 
      poor solubility in water i.e. 0.05 mg/mL. It suffers from poor bioavailability 
      due to being highly metabolized by the liver and intestine. Surprisingly, RSV 
      metabolites also induce the metabolism of RSV. Hence, significantly less amount 
      of RSV presented in the urine in the unchanged form. Due to some challenges like 
      poor bioavailability, less aqueous solubility, and retention time in the body, 
      researchers concluded to make the nanocarriers for better delivery. Adopting the 
      technique of nano-formulations, increased topical penetration by up to 21%, 
      improved nano-encapsulation and consequently improved bioavailability and 
      permeability by many folds. Hence, the present review describes the complete 
      profile of RSV and its nano-formulations for improving anti-cancer activity along 
      with a patent survey.
CI  - (c) The Author(s) 2022.
FAU - Kumar, Akshay
AU  - Kumar A
AUID- ORCID: 0000-0002-9666-7998
AD  - Department of Quality Assurance, ISF College of Pharmacy, GT Road, Moga 142001, 
      Punjab, India.
FAU - Kurmi, Balak Das
AU  - Kurmi BD
AUID- ORCID: 0000-0001-8470-6622
AD  - Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, 
      Punjab, India.
FAU - Singh, Amrinder
AU  - Singh A
AUID- ORCID: 0000-0002-1724-1420
AD  - Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, 
      Punjab, India.
FAU - Singh, Dilpreet
AU  - Singh D
AUID- ORCID: 0000-0001-8286-3800
AD  - Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, 
      Punjab, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221031
PL  - United States
TA  - Explor Target Antitumor Ther
JT  - Exploration of targeted anti-tumor therapy
JID - 101770662
PMC - PMC9630550
OTO - NOTNLM
OT  - Resveratrol
OT  - cancer
OT  - nano-formulations
OT  - solubility
OT  - synergism
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/11/08 06:00
MHDA- 2022/11/08 06:01
PMCR- 2022/10/31
CRDT- 2022/11/07 04:29
PHST- 2022/08/01 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/11/07 04:29 [entrez]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/08 06:01 [medline]
PHST- 2022/10/31 00:00 [pmc-release]
AID - etat-03-1002105 [pii]
AID - 10.37349/etat.2022.00105 [doi]
PST - ppublish
SO  - Explor Target Antitumor Ther. 2022;3(5):643-658. doi: 10.37349/etat.2022.00105. 
      Epub 2022 Oct 31.